Molecular analysis of the KIT gene in gastrointestinal stromal tumors with novel mutations.

Gizem Calibasi, Yasemin Baskin, Hakan Alyuruk, Levent Cavas, Ilhan Oztop, Ozgul Sagol, Koray Atila, Hulya Ellidokuz, Ugur Yilmaz
{"title":"Molecular analysis of the KIT gene in gastrointestinal stromal tumors with novel mutations.","authors":"Gizem Calibasi,&nbsp;Yasemin Baskin,&nbsp;Hakan Alyuruk,&nbsp;Levent Cavas,&nbsp;Ilhan Oztop,&nbsp;Ozgul Sagol,&nbsp;Koray Atila,&nbsp;Hulya Ellidokuz,&nbsp;Ugur Yilmaz","doi":"10.1097/PAI.0b013e318284a074","DOIUrl":null,"url":null,"abstract":"<p><p>Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. KIT gene mutations have great importance for GISTs. This study evaluated the relationship between KIT mutations and GIST clinicopathologic features to define region-specific and population-specific differences. Genomic DNA was extracted from 60 GISTs, and polymerase chain reaction was performed for KIT gene exons 9, 11, 13, and 17. Polymerase chain reaction amplicons were sequenced in both directions. This study represents the first mutation data of the KIT gene in GISTs from a Turkish population and reports novel mutations. The mutation rate in exon 11 (46.7%) was remarkably higher than those of the other exons (8.3% for exon 9; 11.7% for exon 13; 1.7% for exon 17). There was an association between malignancy potential and the presence of KIT mutations (odds ratio=3.18). Cases with mutations in codons W557-K558 in exon 11 had 11-fold greater risk of malignancy when compared with those without a mutation in this exon (odds ratio=11). We report different mutations than those previously reported, which emphasizes the importance of personalized medicine that could be empowered by the use of bioinformatics tools in the diagnostic process and therapeutic approaches.</p>","PeriodicalId":520562,"journal":{"name":"Applied immunohistochemistry & molecular morphology : AIMM","volume":" ","pages":"37-45"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/PAI.0b013e318284a074","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied immunohistochemistry & molecular morphology : AIMM","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PAI.0b013e318284a074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. KIT gene mutations have great importance for GISTs. This study evaluated the relationship between KIT mutations and GIST clinicopathologic features to define region-specific and population-specific differences. Genomic DNA was extracted from 60 GISTs, and polymerase chain reaction was performed for KIT gene exons 9, 11, 13, and 17. Polymerase chain reaction amplicons were sequenced in both directions. This study represents the first mutation data of the KIT gene in GISTs from a Turkish population and reports novel mutations. The mutation rate in exon 11 (46.7%) was remarkably higher than those of the other exons (8.3% for exon 9; 11.7% for exon 13; 1.7% for exon 17). There was an association between malignancy potential and the presence of KIT mutations (odds ratio=3.18). Cases with mutations in codons W557-K558 in exon 11 had 11-fold greater risk of malignancy when compared with those without a mutation in this exon (odds ratio=11). We report different mutations than those previously reported, which emphasizes the importance of personalized medicine that could be empowered by the use of bioinformatics tools in the diagnostic process and therapeutic approaches.

新突变胃肠道间质瘤中KIT基因的分子分析。
胃肠道间质瘤(gist)是最常见的胃肠道间质肿瘤。KIT基因突变对gist有重要意义。本研究评估了KIT突变与GIST临床病理特征之间的关系,以确定区域特异性和人群特异性差异。从60个gist中提取基因组DNA,对KIT基因外显子9、11、13和17进行聚合酶链反应。在两个方向上对聚合酶链反应扩增子进行测序。这项研究代表了来自土耳其人群的gist中KIT基因的第一个突变数据,并报告了新的突变。外显子11的突变率(46.7%)显著高于其他外显子(8.3%;外显子13为11.7%;外显子17为1.7%)。恶性潜能与KIT突变存在相关性(优势比=3.18)。第11外显子W557-K558密码子突变的患者患恶性肿瘤的风险是没有该外显子突变的患者的11倍(优势比=11)。我们报告的突变与以前报道的不同,这强调了个性化医疗的重要性,可以通过在诊断过程和治疗方法中使用生物信息学工具来增强。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信